Complement provides a key immunologic defense against invading pathogens; thus, a clear understanding of the interactions between cytomegalovirus (CMV) and complement may permit the development of strategies to enhance CMV neutralization. In the presence of specific anti-CMV antibodies, complement enhanced the neutralizing ability of serum by 2-to 3-fold. However, in the absence of specific anti-CMV antibodies, complement was ineffective in neutralizing CMV virions by plaque assay. Although complement alone did not mediate any neutralizing effect, CMV consumed complement activity from seronegative serum, resulting in the deposition of C3 on the virion. However, only in the presence of specific anti-CMV antibody did complement activation continue to the deposition of C9 on the virions. These results strongly suggest complement regulation by CMV virions that is modulated by anti-CMV antibody; this regulation may be attributed to three host complement regulators on the virions: CD55, CD46, and CD59.
Complement provides a main line of immunologic defense tent persons also results in a normal humoral response and the subsequent generation of stable levels of anti-CMV IgG against invading pathogens. The complement system consists of at least 22 immunologically non -cross-reactive and distinct antibodies. The antibodies generated have been reported to be directed against both CMV early (nonstructural) and CMV late plasma proteins. Together they represent a significant proportion of the plasma proteins, as their cumulative concentration (structural) proteins [12 -21] . However, serum samples from subjects with cytomegalic inclusion disease show significantly exceeds 3 mg/mL. On activation, these proteins interact with membranes and with one another in an orderly sequential manbroader immune responses than do sera from healthy CMV antibody carriers [12] . The addition of exogenous complement ner (reviewed in [1, 2] ). Antibody-activated complement-mediated cytolysis and virolysis are two of the primary mechanisms to commercial IgG preparations can enhance the neutralization of CMV by 2-to 16-fold [22 -24] . However, the mechanism by which the host immune system eliminates virally infected cells and virus, respectively (reviewed in [3] ). However, many by which complement enhances antibody-mediated neutralization -for example, by steric hindrance or virolysis -has not viruses, including influenza virus, Newcastle disease virus, mumps virus, and certain type C retroviruses, are neutralized been elucidated, nor are the effects of complement on CMV virions in the absence of specific anti-CMV antibodies underby complement in the absence of specific anti-virus antibodies (reviewed in [4] ).
stood. We investigated the role of complement in neutralizing CMV While in most normal immunocompetent persons, the cellular immunity seems to control human cytomegalovirus (CMV) in the presence and absence of specific anti-CMV antibody, as well as the complement-consuming capabilities of the CMV infection [5 -8] . CMV is associated with morbidity and mortality in congenitally infected infants and immunosuppressed pavirion. We also investigated the predominant pathway of complement activation. tients. CMV infection has also been reported to be associated with a higher rate of graft rejection or development of graftversus-host disease [9 -11] . CMV infection of immunocompe-
Materials and Methods
Materials. Bovine serum albumin (BSA, fraction V), EDTA, and EGTA were obtained from Sigma (St. Louis). All ultracentri-JID 1997;176 (August) The intrinsic complement activity was inhibited in the FBS by were depleted of IgG by use of a protein G-sepharose column (Pharmacia, Uppsala, Sweden) as per manufacturer's instructions, incubation of the serum at 56ЊC for 1 h before addition to cell medium. Contamination of the cells by Mycoplasma organisms resulting in the removal of all anti-CMV antibodies. These depleted sera were confirmed as seronegative by EIA (Abbott), the absence was ruled out by use of ELISA (Mycoplasma PCR ELISA kit; Boehringer Mannheim, Montreal). The laboratory strain of human of IgG was confirmed by Western blot analysis, and the serum was concentrated to its original volume by use of a centrifugal CMV, AD169, was obtained from the American Type Culture Collection (Rockville, MD) and was used to infect fibroblasts at concentrator (Amicon Canada, Oakville, Canada) with a molecular mass cutoff of 10 kDa. The complement activity of the depleted an MOI of 10 for Western blot analysis or at an MOI of õ0.01 to generate CMV virion stocks. After cell supernatants were serum was assessed by the clinical hematology laboratory at University Hospital by use of a CH 50 assay and found to be at the low cleared by low-speed centrifugation (250 g), CMV virions were purified by separation in a discontinuous 10%-60% sucrose gradiend of the normal range (classical pathway Å 114-202, alternative pathway Å 92-152). ent in a high-speed ultracentrifuge at 15,000 g for 2 h at 4ЊC. CMV virions were extracted from an opalescent band at the interStandard plaque assay and neutralization assay. Serially diluted samples of virus stocks were used to infect fibroblast cultures face between the 50% and 60% sucrose layers and washed in 3 mL of TBS (12.5 mM TRIS, pH 7.4, 0.88% NaCl) by centrifugaat 85% confluence. Cells were overlaid with DMEM with 10% FBS containing 1% agarose or overlaid with DMEM with 5% FBS tion (18,000 g, 30 min, 4ЊC). As a control, a number of fibroblasts equal to that used for initial virus propagation were disrupted by containing 0.05 mg/mL human IgG (containing high titers of anti-CMV antibodies as determined by functional neutralization assay). repeatedly passing the cells through a 25-gauge needle, then treating the resultant suspension as though it were the supernatant Triplicate cultures were processed for each serum dilution and visualized 10-14 days after infection by staining the monolayers containing CMV from a virus propagation. Even though no bands were seen on the discontinuous sucrose gradient nor any pellet in with 0.05% methylene blue following fixation with 5% formaldehyde in PBS. subsequent centrifugation steps, the samples were collected at the same level and treated in an manner identical to that used for For the neutralization assay, 150 mL of a constant titer of virus (80 plaques/10 cm 2 ) was mixed and incubated with 150 mL of samples containing CMV virions (cell lysate control).
Antibodies. Murine monoclonal antibodies directed against serially diluted serum samples. After 30 min of incubation at 37ЊC, 100 mL/well (triplicate) of each dilution was incubated for 1 h at CD46 were obtained from Bruce Loveland (Austin Research Institute, Melbourne). Monoclonal antibodies against CD55 were ob-37ЊC with a layer of fibroblasts; the cells were then washed once, and the formation of plaques was allowed to proceed over the next tained from Wendell Rosse (Duke University, Durham, NC) and B. Paul Morgan (University of Wales, Cardiff, UK), monoclonal 14-16 days, at the end of which time the plaques were enumerated. The number of CMV plaques subsequently produced was inversely anti-CD59 was obtained from Charles J. Parker (University of Utah, Salt Lake City), and monoclonal antibody against the transproportional to that sample's ability to neutralize the virus; the dilution of serum that yielded half of the plaques compared with ferrin receptor, CD71, was obtained from Wilf Jefferies (University of British Columbia). Peroxidase-conjugated goat anti-rabbit virus mixed with cell medium only was reported as the inverse of the dilution (NT 50 ). Samples were categorized as seronegative (no IgG and goat anti-mouse IgG were purchased from Jackson Immunoresearch Laboratories (Avondale, PA). Polyclonal rabbit antispecific anti-CMV antibodies detectable) or seropositive on the basis of ELISA results provided by the infectious diseases refer-CD55 was raised in this laboratory by use of decay-accelerating factor isolated from human red blood cells by the method of Nichence laboratory at the Vancouver Centre-Canadian Red Cross Society Blood Services. All serum samples were also assayed for intrinolson-Weller et al. [29] , polyclonal rabbit anti-CD59 was a gift of C. J. Parker, and polyclonal anti-CR1 was a gift of B. Paul Morgan. sic CMV, but none were found to be positive. The unbound virus was removed by rinsing the cell layers with PBS, and the plaque Polyclonal goat anti-human C3 and anti-human C9 were purchased from Quidel, peroxidase-conjugated rabbit anti-goat IgG assay was performed as above. One variation of the described neutralization assay was used, in which aliquots of the undiluted and donkey anti-human IgG antibodies were purchased from Jackson Immunoresearch Laboratories, and normal rabbit serum, used virus stock were incubated with undiluted serum for 30 min at 37ЊC, and then the amount of remaining infectious virus was asceras a negative control in Western blot analysis, was purchased from Cedarlane Laboratories (Hornby, Canada).
tained by standard plaque assay. Western blot analysis. Roughly equal numbers of cells, 10 6
Serum samples. Serum samples were obtained from healthy volunteers. The serum was immediately separated and divided into pfu of CMV, or 20 ng of purified CD55 or CD59 were loaded and separated by nonreducing SDS-PAGE [30] . Purified erythrocyte sterile 250-mL aliquots and frozen immediately at 070ЊC. Samples were used within 4 months of collection to ensure that the comple-CD55 and CD59 were gifts of Carmen van den Berg (University of Wales College of Medicine, Cardiff, UK). Cells were disaggrement activity in the samples remained optimal. Some aliquots were heated at 56ЊC for 30 min to inactivate the complement when gated by use of 15 mM EDTA in PBS containing 30 mM sodium azide, counted, and resuspended and lysed in nonreducing sample required. Aliquots from all serum samples were tested by the Vancouver Centre-Canadian Red Cross Society Blood Services for the buffer [30] . For investigation of complement components co-purifying with virions, gels were run under reducing conditions. presence of CMV antibodies by EIA (CMV Total Ab EIA; Abbott Laboratories, Hamilton, Canada). All serum samples were coded Prestained protein standards (Amersham, Oakville, Canada) and prestained protein standards (Life Technologies) were used as moand all subsequent experiments performed blind as to the results of the CMV antibody test. The anti-CMV antibody status of most lecular mass standards. Proteins were transferred to nitrocellulose membrane, blocked with 3% powdered milk and 3% BSA in TBSof the subjects was measured at intervals of 4-6 months. Serum samples from subjects who had been seropositive for ú6 months T (TBS with 0.05% Tween 20), probed with specific polyclonal or
Results
antibodies were detected with a horseradish peroxidase-conju-
The first set of experiments was designed to determine the tion of seropositive serum decreased the neutralization activity, mL of seropositive serum depleted of IgG, or CMV-seronegative and adding rabbit complement increased the activity greatly serum. A control containing only CMV-seropositive serum and (table 1) . The difference between the effects of the intrinsic 100 mL of GVB was also included to ensure that the postincubacomplement and the added rabbit complement likely represents tion washes removed the unbound complement components. All mixtures were incubated for 30 min at 37ЊC; the reactions were the relative dilution of the intrinsic complement, coincident stopped by the addition of excess GVB containing 15 mM EDTA with the dilution of the antibodies, since the rabbit complement (GVB-EDTA) followed by centrifugation at 18,000 g. The pellet alone had no neutralizing ability. by measuring decrease in plaque-forming units rather than senents were removed. After the final purification step, the rerum dilution values. After a 30-min incubation of the undiluted sulting pellet was resuspended in 100 mL of 21 reducing sample virus stock in fresh cell media at 37ЊC, the amount of remaining buffer, and 25 mL for each sample was used for Western blot analysis.
virus was slightly reduced from 5.0 { 0. reduced that serum sample's ability to neutralize CMV to the significant test and Bonferroni's correction for multiple comparisons was used to identify differences between groups.
level of a seronegative serum sample (data not shown).
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NOTE. Data are % of plaque-forming units remaining after 30-min incubation at 37ЊC with serum compared with identical virus aliquots incubated with cell medium (mean { SD, rounded to nearest whole number, for triplicate values). Note that dilutions for seronegative samples start at 1/2, while dilutions for seropositive serum samples start at 1/16. Neutralizing ability of each serum sample was also compared with that of identical samples in which intrinsic complement was heat-inactivated (heated) or in which exogenous rabbit complement was added (/rab C).
The next set of experiments was designed to evaluate the complete consumption of intrinsic complement activity until the serum was first diluted 1:2 to 1:4 with GVB 2/
. By contrast, effect of human CMV on the activity of complement in the seropositive and seronegative serum samples. When CMV was even though the complement in the seronegative serum samples was found to have a negligible effect on the neutralization of mixed with seropositive serum samples and incubated for 30 min at 37ЊC, varying degrees of complement consumption were CMV, addition of CMV to seronegative serum samples routinely resulted in a reduction of the complement activity (figure seen, depending on the serum sample tested (figure 2). All values are given as a percentage of the complement activity of 2). Compared with serum samples incubated without virus for 30 min at 37ЊC, the reduction in complement activity was serum treated identically except for the addition of virus. Addition of CMV to some seropositive serum samples resulted in significant when CMV was mixed with serum diluted 1:2 (P õ .05). The decrease in residual complement activity became a complete consumption of the intrinsic complement activity, even when 5 1 10 6 pfu of CMV was mixed 1:1 with undiluted more notable with subsequent serum dilutions, until almost all of the complement activity was consumed when CMV was serum (figure 2). Other seropositive samples resulted in a significant decrease in complement activity but did not result in mixed with a 1:8 dilution of seronegative serum (P õ .001).
/ 9d2f$$au24 06-10-97 14:56:36 jinfa UC: J Infect The amount of residual complement activity in seropositive serum samples mixed with virus was always lower (figure 2), held constant at a 1:4 dilution and the amount of virus added was serially diluted (figure 3). In both seropositive and seronegative sera, almost all of the complement activity was consumed in seronegative samples. Regardless of the CMV serologic staby 5 1 10 6 pfu of CMV following a 30-min incubation at tus of the serum, addition of 5 1 10 3 pfu of CMV to a 1:4 37ЊC. However, the complement-consuming ability of CMV dilution of serum consumed a negligible amount of complewas always 10-fold greater in seropositive serum samples than ment.
To investigate the possible deposition of complement components on the surface of CMV virions, Western blot analysis was performed on virions following incubation with serum and removal of unbound complement components. The unbound complement components were removed by pelleting the virus through a 30% sucrose layer. After incubation with seropositive serum, human IgG was found to co-purify with the CMV virions ( figure 4A ). The binding of IgG was unaffected by the presence of EGTA, a specific inhibitor of the classical complement activation pathway, or EDTA, an inhibitor of both the classical and alternative complement activation pathways. If IgG was depleted from the seropositive samples, no band at ; figure 4B) or under physiologic ionic strength conditions (all components suspended in TBS; data not shown). These high-molecular-mass bands may represent a larger amount of C3 covalently bound to virion proteins and glycoproteins; this interpretation is supported by the absence of any bands greater than the native 115-kDa C3 a-chain for the nonspecific association of C3 observed in the presence of EDTA.
The differential degree of complement activation under the various conditions is best exemplified by the investigations for C9 ( figure 4C) . No C9 was found to associate with the virions in the presence of EDTA, suggesting minimal nonspecific association. The amount of C9 associated with seronegative serum and IgG-depleted seropositive serum was negligible, a little more was observed with seropositive serum plus EGTA, and the most C9 was detected when virions were incubated with seropositive serum in the absence of EGTA or EDTA. Again, these results were the same whether the experiment was conducted under low (figure 4C) or physiologic ionic strength conditions (data not shown). This suggests that minimal complete activation of complement occurred in the absence of anti-CMV antibodies, but when anti-CMV antibodies were present, activation occurred mainly by the classical pathway and proceeded to completion with the deposition of C9 onto the virions.
The negligible levels of C9 on the virions that had evidence of C3 deposition following incubation with seronegative serum number of fibroblasts (equal to the amount used to propagate Proteins were transferred to nitrocellulose and blots reacted with (A) the virus) with a fine needle, and the cell debris was then treated anti-IgG, (B) anti-C3, or (C) anti-C9 as described.
in a manner identical to that used for the virus preparation. This control addressed the possible nonspecific co-migration of host cell complement inhibitors to the same density at which CMV Next, we investigated the presence of C3 with CMV virions (figure 4B). The co-purification of C3 with virions incubated virions are found, thereby causing artifacts. The presence of CD46, CD55, and CD59 were observed in the lanes with puriwith seropositive serum in the presence of EDTA (where no complement activation should occur) indicated a low level of fied CMV virions ( figure 5 ), but the presence of CD35, not expressed on fibroblasts, or CD71, present on uninfected finonspecific association of C3 with CMV virions under the experimental conditions used. The amounts of C3 associated broblasts, was not observed (data not shown). In some experiments, a trace amount of CD59 was seen in the cell lysate with the virions incubated with seronegative serum, seropositive serum plus EGTA (in which only the alternative pathway is control lane; however, the intensity of the band was always much less than the amount of CD59 co-purifying with the active), and IgG-depleted seropositive serum were very similar, indicating some activation of the alternative pathway. How-CMV virions. No CD46 or CD55 was ever detected in the lysate control. Further, the apparent molecular mass for the ever, there was a higher signal intensity in the region of the gel containing higher-molecular-mass bands (ú150 kDa), CD55 associated with virions was more variable than that for the CD55 found on uninfected fibroblasts or fibroblasts infected which were reactive with anti-C3 antibody when the virions were incubated with seropositive serum in the absence of comwith CMV for 72 h ( figure 5C ). Cross-reactivity of the anti-CD55 monoclonal antibody with a viral protein was ruled out plement inhibitors, compared with the other lanes ( figure 4B) . These results were identical whether the experiment was perby obtaining similar results with monoclonal anti-CD55 anti-host-encoded complement regulatory proteins CD55 and CD59 with purified CMV virions, and we also found a third hostcomplement regulator, CD46. The presence of host-complement inhibitors on virions has also been reported for human immunodeficiency virus [37, 38] . The acquisition of host proteins by budding virions may be serendipitous, as proteolipids such as CD55 and CD59 are readily incorporated into foreign membranes [39, 40] ; and CMV infection of fibroblasts results in an 8-fold and 3-fold increase in the expression of CD55 and CD46, respectively, which enhances the infected cell's ability to decrease complement-mediated lysis [41] . Alternatively, incorporation of host-encoded complement regulators may represent a viral strategy to evade host immune defenses. We are currently developing techniques to quantitate the amount of CD55, CD46, and CD59 on each virion and investigating the point in the replication and egress of the virion at which it acquires these host molecules.
The inactivation of intrinsic complement or addition of exogenous complement did not have any measurable effect on the functional neutralization of CMV by seronegative serum sam- may account for the lower neutralization ranges reported by There was also no homology found between the region bound other investigators and the hypersensitivity of our assay used in by the anti-CD55 monoclonal antibody and the published setable 1 (i.e., ''neutralization'' by seronegative serum samples). quence of AD169 as determined by the computer programs Addition of exogenous complement to seropositive serum Geneworks and DNA Strider. The relative mobility of the CD46 samples increased the CMV-neutralizing ability of serum by on the purified virions was not as variable as that of the virion 2-to 3-fold, and similarly, heat-inactivation of the intrinsic CD55; nevertheless, the virion CD46 had a slightly increased complement decreased the CMV-neutralizing ability, which is molecular mass compared with that of CD46 on uninfected fiin agreement with reports measuring the influence of complebroblasts or fibroblasts infected with CMV for 72 h. ment on anti-CMV IgG preparations [22 -24] . It is interesting to note, however, that some anti-CMV murine monoclonal antibodies require complement to exhibit neutralizing activity Discussion [15, 21] . Furthermore, Graham et al. [43] found that injecting simian CMV into monkeys led to the production of non -comThe data reported herein demonstrate that while complement, in the absence of specific anti-CMV antibodies, was ineffective plement-requiring neutralizing antibodies but that human CMV used in the same model led to a preferential production of at mediating neutralization of the virus, CMV virions were capable of activating complement in the absence of specific complement-requiring neutralizing antibodies. We have found that the degree of neutralizing ability for each seropositive antibody and that C3 activation fragments were associated with the virions. Further, negligible amounts of C9 were found on serum sample did not correlate with the total anti-CMV antibody concentration (data not shown), a conclusion supported virions containing C3 activation fragments unless specific anti-CMV antibodies were present. These latter findings suggest by numerous other investigators for CMV and herpes simplex virus [44 -49] . that CMV virions possess a complement-regulating ability that is not readily explainable in the absence of a CMV-encoded
The Western blot analysis of virions incubated with seronegative serum showed traces of co-purifying IgG, but this may C3 binding protein [36] or any other viral complement regulators. In agreement with Spear et al. [37] , we have detected the represent IgG bound to a CMV virion Fc receptor [33 -35] IgG-detecting ELISA method was used to investigate the pres- effects of these chelators on other plasma proteins that may
